Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$34.54 USD
-0.04 (-0.12%)
Updated May 3, 2024 04:00 PM ET
After-Market: $34.51 -0.03 (-0.09%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$34.54 USD
-0.04 (-0.12%)
Updated May 3, 2024 04:00 PM ET
After-Market: $34.51 -0.03 (-0.09%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Zacks News
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -5.85% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More
by Zacks Equity Research
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat
by Zacks Equity Research
Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Agios Pharmaceuticals (AGIO) Down 24.6% Since Last Earnings Report?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.07% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
by Zacks Equity Research
Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.
Agios' (AGIO) Q2 Loss Narrows, Pipeline Makes Solid Progress
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 2.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.
Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat
by Zacks Equity Research
Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress
by Zacks Equity Research
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Agios Pharmaceuticals (AGIO) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates
by Zacks Equity Research
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.
Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up
by Zacks Equity Research
Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely focus on developing treatments for genetically defined diseases. Shares rise.
Agios Pharmaceuticals (AGIO) Up 6.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal
by Zacks Equity Research
Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.
Agios' (AGIO) Mitapivat Gets Orphan Drug Tag to Treat SCD
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.